Haemonetics Corporation Company Profile (NYSE:HAE)

About Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:HAE
  • CUSIP: 40502410
  • Web: www.haemonetics.com
  • Market Cap: $2.08907 billion
  • Outstanding Shares: 52,464,000
Average Prices:
  • 50 Day Moving Avg: $40.13
  • 200 Day Moving Avg: $40.04
  • 52 Week Range: $29.17 - $43.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.51
  • P/E Growth: 3.24
Sales & Book Value:
  • Annual Revenue: $886.12 million
  • Price / Sales: 2.37
  • Book Value: $14.15 per share
  • Price / Book: 2.82
  • EBIDTA: $139.74 million
  • Net Margins: -2.96%
  • Return on Equity: 10.66%
  • Return on Assets: 6.10%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 2.42%
  • Quick Ratio: 1.58%
  • Average Volume: 314,614 shs.
  • Beta: 0.89
  • Short Ratio: 9.35
Frequently Asked Questions for Haemonetics Corporation (NYSE:HAE)

What is Haemonetics Corporation's stock symbol?

Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How were Haemonetics Corporation's earnings last quarter?

Haemonetics Corporation (NYSE:HAE) issued its quarterly earnings results on Monday, May, 8th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.37 by $0.02. The business had revenue of $228.10 million for the quarter, compared to the consensus estimate of $215.06 million. Haemonetics Corporation had a negative net margin of 2.96% and a positive return on equity of 10.66%. The firm's quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.37 EPS. View Haemonetics Corporation's Earnings History.

What guidance has Haemonetics Corporation issued on next quarter's earnings?

Haemonetics Corporation issued an update on its FY18 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $1.55-1.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.59. The company issued revenue guidance of to approximate FY17 of $886.1 million, compared to the consensus revenue estimate of $899.98 million.

Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?

8 brokers have issued 12 month price targets for Haemonetics Corporation's shares. Their forecasts range from $24.00 to $50.00. On average, they expect Haemonetics Corporation's share price to reach $37.86 in the next year. View Analyst Ratings for Haemonetics Corporation.

Who are some of Haemonetics Corporation's key competitors?

Who are Haemonetics Corporation's key executives?

Haemonetics Corporation's management team includes the folowing people:

  • Christopher Simon, President, Chief Executive Officer, Director
  • William P. Burke, Chief Financial Officer, Executive Vice President
  • Michelle Basil, Executive Vice President, General Counsel
  • Neil Ryding, Executive Vice President, Global Operations
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board
  • Catherine M. Burzik, Independent Director
  • Charles J. Dockendorff, Independent Director
  • Susan Bartlett Foote, Independent Director
  • Ronald G. Gelbman, Independent Director

Who owns Haemonetics Corporation stock?

Haemonetics Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Van Berkom & Associates Inc. (2.30%), Hermes Investment Management Ltd. (1.31%), BTIM Corp. (0.57%), Fisher Asset Management LLC (0.46%), Confluence Investment Management LLC (0.10%) and US Bancorp DE (0.04%). Company insiders that own Haemonetics Corporation stock include Brian Concannon, Byron Selman, Christopher J Lindop, Christopher Simon, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics Corporation.

Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?

Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including BTIM Corp., Hermes Investment Management Ltd., First Quadrant L P CA, Capstone Asset Management Co., Confluence Investment Management LLC and Fisher Asset Management LLC. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics Corporation.

Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?

Haemonetics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Van Berkom & Associates Inc., Legato Capital Management LLC, Fox Run Management L.L.C., Eqis Capital Management Inc., State of Alaska Department of Revenue, Kirr Marbach & Co. LLC IN, Aperio Group LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Haemonetics Corporation.

How do I buy Haemonetics Corporation stock?

Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics Corporation's stock price today?

One share of Haemonetics Corporation stock can currently be purchased for approximately $39.96.

MarketBeat Community Rating for Haemonetics Corporation (NYSE HAE)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Haemonetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $37.86 (5.26% downside)

Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/13/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$50.00HighView Rating Details
5/8/2017Jefferies Group LLCReiterated RatingBuy$42.00MediumView Rating Details
2/7/2017Barrington ResearchDowngradeOutperform -> Market PerformN/AView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016Benchmark Co.Boost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$29.00N/AView Rating Details
5/12/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/23/2015Raymond James Financial, Inc.DowngradeMarket Perform -> UnderperformN/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Haemonetics Corporation (NYSE:HAE)
Earnings by Quarter for Haemonetics Corporation (NYSE:HAE)
Earnings History by Quarter for Haemonetics Corporation (NYSE HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Haemonetics Corporation (NYSE:HAE)
2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $1.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.37$0.42$0.39
Q4 20173$0.35$0.38$0.36
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.43$0.47$0.44
Q4 20182$0.39$0.41$0.40
Q1 20191$0.25$0.25$0.25
Q2 20191$0.45$0.45$0.45
Q3 20191$0.47$0.47$0.47
Q4 20191$0.42$0.42$0.42
(Data provided by Zacks Investment Research)


Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Haemonetics Corporation (NYSE:HAE)
Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.43View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.90View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Haemonetics Corporation (NYSE:HAE)
Latest Headlines for Haemonetics Corporation (NYSE:HAE)
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : July 24, 2017
finance.yahoo.com - July 24 at 10:00 PM
finance.yahoo.com logoHaemonetics Sets Date for Publishing 1st Quarter Fiscal 2018 Results: August 7, 2017
finance.yahoo.com - July 18 at 9:17 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Rating Increased to Outperform at JMP Securities
www.americanbankingnews.com - July 16 at 7:02 PM
americanbankingnews.com logoHaemonetics Corporation (NYSE:HAE) Expected to Post Quarterly Sales of $213.55 Million
www.americanbankingnews.com - July 14 at 2:06 PM
finance.yahoo.com logoBelieve In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform
finance.yahoo.com - July 13 at 8:59 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM
americanbankingnews.com logo Brokerages Anticipate Haemonetics Corporation (HAE) to Announce $0.31 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 11 at 12:40 AM
finance.yahoo.com logoETFs with exposure to Haemonetics Corp. : July 6, 2017
finance.yahoo.com - July 7 at 5:58 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Lowered to Sell at BidaskClub
www.americanbankingnews.com - June 23 at 9:00 PM
finance.yahoo.com logoHaemonetics Announces Formation of Scientific Advisory Council
finance.yahoo.com - June 23 at 2:58 AM
americanbankingnews.com logo Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - June 18 at 9:42 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Expected to Post Earnings of $0.31 Per Share
www.americanbankingnews.com - June 16 at 12:32 PM
finance.yahoo.com logoHaemonetics Will Webcast Investor and Analyst Meeting
finance.yahoo.com - June 14 at 7:06 PM
finance.yahoo.com logoHaemonetics Rides on Solid Plasma, Slows Blood Center Growth
finance.yahoo.com - June 14 at 7:06 PM
finance.yahoo.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: Q4, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 14 at 12:46 AM
finance.yahoo.com logoETFs with exposure to Haemonetics Corp. : June 13, 2017
finance.yahoo.com - June 13 at 5:24 PM
finance.yahoo.com logoHaemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 11:08 AM
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : June 13, 2017
finance.yahoo.com - June 13 at 11:08 AM
finance.yahoo.com logoETFs with exposure to Haemonetics Corp. : May 30, 2017
finance.yahoo.com - May 30 at 5:30 PM
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : May 29, 2017
finance.yahoo.com - May 29 at 9:56 AM
finance.yahoo.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 26 at 6:17 PM
finance.yahoo.com logoHaemonetics Corp (HAE) Files 10-K for the Fiscal Year Ended on March 31, 2017
finance.yahoo.com - May 25 at 3:47 AM
americanbankingnews.com logoHaemonetics Co. (HAE) Director Sells $704,605.43 in Stock
www.americanbankingnews.com - May 24 at 10:35 PM
bizjournals.com logoApheresis Equipment Market is expected to reach USD 3.7 billion by 2024
www.bizjournals.com - May 23 at 11:36 AM
finance.yahoo.com logoHaemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017
finance.yahoo.com - May 22 at 5:10 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 12:12 AM
finance.yahoo.com logoHaemonetics Corp. – Value Analysis (NYSE:HAE) : May 19, 2017
finance.yahoo.com - May 19 at 5:21 PM
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : May 18, 2017
finance.yahoo.com - May 18 at 9:45 AM
americanbankingnews.com logoTheStreet Lowers Haemonetics Co. (HAE) to C
www.americanbankingnews.com - May 13 at 3:58 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Earn Q1 2019 Earnings of $0.25 Per Share
www.americanbankingnews.com - May 11 at 3:20 PM
americanbankingnews.com logoEquities Analysts Set Expectations for Haemonetics Co.'s FY2018 Earnings (HAE)
www.americanbankingnews.com - May 11 at 2:36 PM
americanbankingnews.com logoFY2018 Earnings Forecast for Haemonetics Co. (HAE) Issued By Jefferies Group
www.americanbankingnews.com - May 11 at 2:36 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Earn FY2018 Earnings of $1.59 Per Share
www.americanbankingnews.com - May 10 at 2:32 PM
americanbankingnews.com logoHaemonetics Co. (HAE) to Post Q1 2018 Earnings of $0.27 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 10 at 1:08 PM
americanbankingnews.com logoBarrington Research Equities Analysts Boost Earnings Estimates for Haemonetics Co. (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM
americanbankingnews.com logoBrokers Offer Predictions for Haemonetics Co.'s Q1 2018 Earnings (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 8-May-17 12:00pm GMT
finance.yahoo.com - May 10 at 12:35 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 9 at 5:02 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 8 at 10:16 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 8:56 PM
seekingalpha.com logoHaemonetics (HAE) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:19 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 11:38 AM
finance.yahoo.com logoHaemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance Available on Investor Relations Website
finance.yahoo.com - May 8 at 8:15 AM
finance.yahoo.com logoHaemonetics reports 4Q loss
finance.yahoo.com - May 8 at 8:15 AM
seekingalpha.com logoHaemonetics beats by $0.01, beats on revenue
seekingalpha.com - May 8 at 6:25 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 4 at 8:22 PM
americanbankingnews.com logoSomewhat Critical Press Coverage Very Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 1 at 3:42 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Announce Quarterly Sales of $221.08 Million
www.americanbankingnews.com - April 30 at 9:12 AM



Haemonetics Corporation (HAE) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff